公开(公告)号：US20230354701A1

公开(公告)日：2023-11-02

申请号：US18211434

申请日：2023-06-19

Applicant: Merck Patent GmbH

Inventor： Philipp STOESSEL ,  Christian EHRENREICH ,  Philipp HARBACH

IPC: H10K85/60 ,  C07D251/24 ,  C07D403/10 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/10 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  C07D519/00 ,  C09K11/06 ,  C07D209/86

CPC classification number: H10K85/6572 ,  C07D251/24 ,  C07D403/10 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/10 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  C07D519/00 ,  C09K11/06 ,  H10K85/615 ,  H10K85/622 ,  H10K85/636 ,  H10K85/654 ,  H10K85/657 ,  H10K85/6574 ,  H10K85/6576 ,  C07D209/86 ,  H10K2101/10

Abstract: The present invention describes compounds having an acceptor group and a donor group, especially for use in electronic devices. The invention further relates to a process for preparing the compounds of the invention and to electronic devices comprising these.

公开(公告)号：US20230346797A1

公开(公告)日：2023-11-02

申请号：US18220090

申请日：2023-07-10

Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services

Inventor： Sanjay A. Desai ,  Ajay D. Pillai

IPC: A61K31/553 ,  A61K31/165 ,  A61K31/4155 ,  A61K31/423 ,  A61K31/4245 ,  A61K31/433 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/4741 ,  A61K31/4745 ,  A61K31/50 ,  A61K31/554 ,  A61K45/06 ,  C07D403/08 ,  C07D498/04 ,  C07D263/57 ,  C07D281/16 ,  C07D413/14 ,  C07D417/06 ,  C07D491/048 ,  C07D513/04 ,  A61K31/421

CPC classification number: A61K31/553 ,  A61K31/165 ,  A61K31/4155 ,  A61K31/423 ,  A61K31/4245 ,  A61K31/433 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/4741 ,  A61K31/4745 ,  A61K31/50 ,  A61K31/554 ,  A61K45/06 ,  C07D403/08 ,  C07D498/04 ,  C07D263/57 ,  C07D281/16 ,  C07D413/14 ,  C07D417/06 ,  C07D491/048 ,  C07D513/04 ,  A61K31/421 ,  Y02A50/30

Abstract: Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I,




or a pharmaceutically acceptable salt thereof, wherein R1 to R7 are as described herein.

公开(公告)号：US20230339937A1

公开(公告)日：2023-10-26

申请号：US18002232

申请日：2021-06-18

Applicant: SATO PHARMACEUTICAL CO., LTD.

Inventor： Motoaki BABA ,  Takuma OKUI ,  Yoshiki ITOH

IPC: C07D471/04 ,  C07D491/048 ,  C07D495/04

CPC classification number: C07D471/04 ,  C07D491/048 ,  C07D495/04

Abstract: The present invention provides a compound having a hematopoietic prostaglandin D synthase (H-PGDS) inhibitory activity and being useful for preventing or treating a disease involving the enzyme, and a pharmaceutical composition comprising the compound. Specifically, the present invention provides a compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof:




[wherein R1 represents a hydrogen atom and the like, R2 represents a hydrogen atom and the like, R3 represents a hydrogen atom and the like, R4 represents a hydrogen atom and the like, R5 represents a hydrogen atom and the like, W represents an oxygen atom and the like, and X represents a C1-6 alkyl group and the like.]

公开(公告)号：US20230320205A1

公开(公告)日：2023-10-05

申请号：US18007811

申请日：2021-08-20

Applicant: Shaanxi Lighte Optoelectronics Material Co., Ltd.

Inventor： Tiantian MA ,  Kongyan ZHANG ,  Xinxuan LI

IPC: H10K85/60 ,  C07D405/14 ,  C09K11/06 ,  C07D405/04 ,  C07D491/048 ,  C07D409/14

CPC classification number: H10K85/654 ,  C07D405/14 ,  C09K11/06 ,  H10K85/615 ,  H10K85/6574 ,  C07D405/04 ,  H10K50/11 ,  C07D491/048 ,  H10K85/657 ,  H10K85/6576 ,  C07D409/14 ,  H10K85/626 ,  H10K85/6572

Abstract: The present disclosure belongs to the technical field of organic materials, and provides a nitrogen-containing compound, an organic electroluminescent device, and an electronic apparatus. The nitrogen-containing compound has a structure as shown in a formula 1,

公开(公告)号：US11771692B2

公开(公告)日：2023-10-03

申请号：US16971639

申请日：2019-03-12

Applicant: The Board of Trustees of the Leland Stanford Junior University

Inventor： Sanjay Malhotra ,  Vineet Kumar ,  Dhanir Tailor

IPC: A61P35/00 ,  C07D215/14 ,  C07D491/048 ,  C07D491/153 ,  C07D221/06 ,  C07D221/18 ,  A61K31/4741 ,  A61K31/337 ,  A61K31/473 ,  A61K45/06

CPC classification number: A61K31/4741 ,  A61K31/337 ,  A61K31/473 ,  A61K45/06 ,  A61P35/00 ,  C07D215/14 ,  C07D491/048 ,  C07D491/153

Abstract: Compounds, compositions and methods are provided for the inhibition of GBP1. The subject inhibitor compounds can act by inhibiting GBP1 alone and/or GBP1: pro-survival kinase (e.g. serine/threonine-protein kinase pim-1 (PIM1)) interactions. Aspects of the subject methods include contacting a cellular sample with a GBP 1 inhibitor to inhibit the GBP 1 alone and/or GBP 1: PIM 1 interactions. Also provided are compositions and methods for treating cancer. In certain cases the cancer is resistant towards chemotherapy and radiation therapy.

公开(公告)号：US20230277547A1

公开(公告)日：2023-09-07

申请号：US18175515

申请日：2023-02-27

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： John Patrick Maxwell ,  Paul S. Charifson ,  Qing Tang ,  Steven M. Ronkin ,  Katrina Lee Jackson ,  Albert Charles Pierce ,  David J. Lauffer ,  Pan Li ,  Simon Giroux ,  Jinwang Xu ,  Kevin Michael Cottrell ,  Mark A. Morris ,  Nathan D. Waal ,  John J. Court ,  Wenxin Gu ,  Hongbo Deng

IPC: A61K31/5377 ,  C07D513/04 ,  A61K31/506 ,  A61K31/5386 ,  C07D241/40 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D473/40 ,  C07D475/00 ,  C07D487/04 ,  C07D491/048 ,  C07D498/08 ,  C07D413/04 ,  C07D241/44 ,  C07D491/052 ,  C07D241/42 ,  C07D271/12 ,  C07D401/12 ,  C07D413/14 ,  C07D491/056 ,  C07D491/08

CPC classification number: A61K31/5377 ,  C07D513/04 ,  A61K31/506 ,  A61K31/5386 ,  C07D241/40 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D473/40 ,  C07D475/00 ,  C07D487/04 ,  C07D491/048 ,  C07D498/08 ,  C07D413/04 ,  C07D241/44 ,  C07D491/052 ,  C07D241/42 ,  C07D271/12 ,  C07D401/12 ,  C07D413/14 ,  C07D491/056 ,  C07D491/08

Abstract: The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

公开(公告)号：US11746093B2

公开(公告)日：2023-09-05

申请号：US18010241

申请日：2021-04-02

Applicant: Shaanxi Lighte Optoelectronics Material Co., Ltd.

Inventor： Kongyan Zhang ,  Tiantian Ma ,  Jiamei Cao

IPC: C07D239/26 ,  H10K30/85 ,  H10K85/60 ,  C07D251/24 ,  C07D405/04 ,  C07D405/14 ,  C07D405/10 ,  C07D401/04 ,  C07D409/04 ,  C07D403/04 ,  C07D403/14 ,  C07D409/14 ,  C07D409/10 ,  C07D401/10 ,  C07D403/10 ,  C07D491/048 ,  H10K50/16

CPC classification number: C07D239/26 ,  C07D251/24 ,  C07D401/04 ,  C07D401/10 ,  C07D403/04 ,  C07D403/10 ,  C07D403/14 ,  C07D405/04 ,  C07D405/10 ,  C07D405/14 ,  C07D409/04 ,  C07D409/10 ,  C07D409/14 ,  C07D491/048 ,  H10K30/85 ,  H10K50/16 ,  H10K85/621 ,  H10K85/652 ,  H10K85/654 ,  H10K85/657 ,  H10K85/6572 ,  H10K85/6574 ,  H10K85/6576 ,  C07B2200/05

Abstract: The present disclosure provides a nitrogen-containing compound, an electronic element, and an electronic device, and belongs to the technical field of organic materials. In the nitrogen-containing compound, 1-adamantyl and a cyano group are connected on a nitrogen-containing heteroaryl core structure by a linking group, so that the molecule has a high dipole moment as a whole, organic materials with a high electron mobility can be obtained, and the electron transport properties of the electronic element can be improved, and when the nitrogen-containing compound is used as an electron transport layer of an organic electroluminescent device, the luminous efficiency and service life of the device can be improved, and the operating voltage can be reduced.

公开(公告)号：US20230271975A1

公开(公告)日：2023-08-31

申请号：US18168055

申请日：2023-02-13

Applicant: BioCryst Pharmaceuticals, Inc.

Inventor： PRAVIN L. Kotian ,  Yarlagadda S. Babu ,  V. Satish Kumar ,  Weihe Zhang ,  Peng-Cheng Lu ,  Krishnan Raman

IPC: C07D491/048 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  C07D513/04

CPC classification number: C07D491/048 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  C07D513/04

Abstract: Disclosed are compounds of formula I, II, III, and IV, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula I, II, III, or IV, or pharmaceutically acceptable salt thereof, and methods involving use of the compounds or pharmaceutically acceptable salts thereof and compositions in the treatment and prevention of various diseases and conditions, such as fibrodysplasia ossificans progressiva.

公开(公告)号：US11739061B2

公开(公告)日：2023-08-29

申请号：US17343035

申请日：2021-06-09

Applicant: IDEMITSU KOSAN CO., LTD

Inventor： Satomi Tasaki ,  Masahiro Kawamura ,  Toshinari Ogiwara ,  Hitoshi Kuma ,  Kei Yoshida ,  Keiji Okinaka

IPC: H01L51/54 ,  C07D209/80 ,  C07D209/82 ,  C07D209/94 ,  C07D491/048 ,  C07D491/147 ,  C09K11/06 ,  H10K85/60 ,  H10K50/11

CPC classification number: C07D209/80 ,  C07D209/82 ,  C07D209/94 ,  C07D491/048 ,  C07D491/147 ,  C09K11/06 ,  H10K85/657 ,  H10K85/6572 ,  H10K50/11

Abstract: A compound is represented by a formula (1) below, in which k is an integer of 0 or more, m is an integer of 1 or more, n is an integer of 2 or more. L is a substituted or unsubstituted aromatic hydrocarbon ring having 6 to 30 ring carbon atoms, CN is a cyano group, and D1 and D2 are each independently represented by one of a formula (2), a formula (3) and formula (3x) below, D1 and D2 being optionally mutually the same or different.

公开(公告)号：US11738010B2

公开(公告)日：2023-08-29

申请号：US17385258

申请日：2021-07-26

Applicant: MERCK SHARP & DOHME CORP.

Inventor： John P. Caldwell ,  Reynalda De Jesus ,  Fa-Xiang Ding ,  Charles J. Gill ,  Ginny Dai Ho ,  Sookhee N. Ha ,  Sandra J. Koseoglu ,  Marc A. Labroli ,  Sang Ho Lee ,  Christina Madsen-Duggan ,  Mihir Mandal ,  Terry Roemer ,  Jing Su ,  Christopher Michael Tan ,  Zheng Tan ,  Haifeng Tang ,  Hao Wang ,  Christine Yang ,  Shu-Wei Yang

IPC: A61K31/4439 ,  A61P31/04 ,  A61K31/407 ,  A61K31/421 ,  A61K31/422 ,  A61K31/427 ,  A61K31/431 ,  A61K31/4375 ,  A61K31/438 ,  A61K31/4709 ,  A61K31/5377 ,  A61K31/5383 ,  C07D263/26 ,  C07D413/04 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D491/048 ,  C07D495/04 ,  C07D498/04

CPC classification number: A61K31/4439 ,  A61K31/407 ,  A61K31/421 ,  A61K31/422 ,  A61K31/427 ,  A61K31/431 ,  A61K31/438 ,  A61K31/4375 ,  A61K31/4709 ,  A61K31/5377 ,  A61K31/5383 ,  A61P31/04 ,  C07D263/26 ,  C07D413/04 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D491/048 ,  C07D495/04 ,  C07D498/04

Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a β-lactam antibiotic.